Oxidative metabolism in cancer growth

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 4, 2006, Pages 339-345

  Ristow, Michael ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cancer; Metabolism; Mitochondria; Oxidative phosphorylation

Indexed keywords

ADENOSINE TRIPHOSPHATE; LACTIC ACID;

AEROBIC METABOLISM; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; CELL RESPIRATION; DIET RESTRICTION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; CELL RESPIRATION; ENERGY METABOLISM; GLYCOLYSIS; HOMEOSTASIS; HUMANS; MITOCHONDRIA; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION;

ANIMALIA;

EID: 33746228395     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000232892.43921.98     Document Type: Review

References (104)

1. Pasteur L. Influence de l'oxygene sur le developpement de la levure et la fermentation alcoolique [Influence of oxygen on development of yeast and alcoholic fermentation]. Bull Soc Chim Paris 1861; 28 June:79-80.
2. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science 2001; 292:504-507.
3. Stryer L. Biochemistry. New York: W.H. Freeman and Company; 1995.
4. Tovar J, Leon-Avila G, Sanchez LB, et al. Mitochondrial remnant organelles of Giardia function in iron-sulphur protein maturation. Nature 2003; 426:172-176.
5. Lill R, Mühlenhoff U. Iron-sulfur-protein biogenesis in eukaryotes. Trends Biochem Sci 2005; 30:133-141. A most comprehensive and up-to-date review of one of the most eminent figures in the field of Fe/S synthesis, Roland Lill.
6. Rouault TA, Klausner RD. Iron-sulfur clusters as biosensors of oxidants and iron. Trends Biochem Sci 1996; 21:174-177.
7. Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Tumoren [On metabolism of tumors]. Biochem Z 1924; 152:319-344.
8. Warburg O. The metabolism of tumours. Constable: London; 1930.
9. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
10. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-270.
11. The Nobel Prize in Physiology or Medicine; 1931. http://nobelprize.org/ medicine/laureates/1931/ [last accessed 15 January 2006].
12. Burk D. A colloquial consideration on the Pasteur and Neo-Pasteur effects. Cold Spring Harbor Symposia on Quantitative Biology 1939; 7:420-460.
13. Burk D, Schade AL. On respiratory impairment in cancer cells. Science 1956; 124:270-272.
14. Weinhouse S. On respiratory impairment in cancer cells. Science 1956; 124:267-269.
15. Burk D, Woods M. Newer aspects of glucose fermentation in cancer growth and control. Arch Geschwulstforsch 1967; 28:305-319.
16. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 2004; 313:459-465.
17. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22:190-274.
18. Gause GF. Cancer and mitochondrial D.N.A. BMJ 1969; 3:413-414.
19. Hoberman HD. Is there a role for mitochondrial genes in carcinogenesis? Cancer Res 1975; 35 (11 Pt 2):3332-3335.
20. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20:291-293.
21. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000; 287:2017-2019.
22. Salas A, Yao YG, Macaulay V, et al. A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2005; 2:e296.
23. Shidara Y, Yamagata K, Kanamori T, et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 2005; 65:1655-1663. Experimental demonstration that mtDNA defects result in functional alterations of metabolism.
24. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62:6674-6681.
25. Isidoro A, Martinez M, Fernandez PL, et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004; 378 (Pt 1):17-20.
26. Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26:2095-2104. Third in a series of publications showing impaired expression of ATPsynthase in human cancer specimen (see also Refs [24,25]).
27. Deml E, Oesterle D, Wolff T, Greim H. Age-, sex-, and strain-dependent differences in the induction of enzyme-altered islands in rat liver by diethylnitrosamine. J Cancer Res Clin Oncol 1981; 100:125-134.
28. Racker E. Bioenergetics and the problem of tumor growth. Am Sci 1972; 60:56-63.
29. Racker E, Spector M. Warburg effect revisited: merger of biochemistry and molecular biology. Science 1981; 213:303-307.
30. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286:531-537.
31. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987; 235:1495-1498.
32. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492-1495.
33. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA 1977; 74:3735-3739.
34. Bustamante E, Pedersen PL. Mitochondrial hexokinase of rat hepatoma cells in culture: solubilization and kinetic properties. Biochemistry 1980; 19:4972-4977.
35. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells: requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981; 256:8699-8704.
36. Danial NN, Gramm CF, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424:952-956.
37. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64:3892-3899.
38. Van de Sande T, Roskams T, Lerut E, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 2005; 206:214-219.
39. Bosca L, Mojena M, Ghysdael J, et al. Expression of the v-src or v-fps oncogene increases fructose 2,6-bisphosphate in chick-embryo fibroblasts: novel mechanism for the stimulation of glycolysis by retroviruses. Biochem J 1986; 236:595-599.
40. Chesney J, Mitchell R, Benigni F, et al. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci USA 1999; 96:3047-3052.
41. Atsumi T, Chesney J, Metz C, et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 2002; 62:5881-5887.
42. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88:5680-5684.
43. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24:68-72.
44. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277:23111-23115.
45. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-1320.
46. Maynard MA, Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004; 24:1-13.
47. Hervouet E, Demont J, Pecina P, et al. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 2005; 26:531-539. Outstanding paper linking HIF1α/VHL-activity and OXPHOS.
48. Reynafarje B, Lehninger AL. Ca2+ transport by mitochondria from L1210 mouse ascites tumor cells. Proc Natl Acad Sci USA 1973; 70:1744-1748.
49. Thorne RF, Bygrave FL. Interaction of calcium with mitochondria isolated from Ehrlich ascites tumour cells. Biochem Biophys Res Commun 1973; 50:294-299.
50. LaNoue KF, Hemington JG, Ohnishi T, et al. Defects of anions and electron transport in Morris hepatoma mitochondria. In: McKerns KW, editor. Hormones and cancer. New York: Academic Press; 1974. pp. 131-167.
51. LaNoue KF, Schoolwerth AC. Metabolite transport in mitochondria. Annu Rev Biochem 1979; 48:871-922.
52. Senior AE, McGowan SE, Hilf R. A comparative study of inner membrane enzymes and transport systems in mitochondria from R3230AC mammary tumor and normal rat mammary gland. Cancer Res 1975; 35:2061-2067.
53. Kolarov J, Kuzela S, Krempasky V, Ujhazy V. Some properties of coupled hepatoma mitochondria exhibiting uncoupler-insensitive ATPase activity. Biochem Biophys Res Commun 1973; 55:1173-1179.
54. Kolarov J, Kuzela S, Wielburski A, Nelson BD. The characterization of mitochondrial translation products in rat liver and rat hepatoma cells. FEBS Lett 1981; 126:61-65.
55. Hansford RG, Lehninger AL. Active oxidative decarboxylation of malate by mitochondria isolated from L-1210 ascites tumor cells. Biochem Biophys Res Commun 1973; 51:480-486.
56. Greenhouse WV, Lehninger AL. Magnitude of malate-aspartate reduced nicotinamide adenine dinucleotide shuttle activity in intact respiring tumor cells. Cancer Res 1977; 37:4173-4181.
57. Bloch-Frankenthal L, Langan J, Morris HP, Weinhouse S. Fatty acid oxidation and ketogenesis in transplantable liver tumors. Cancer Res 1965; 25:732-736.
58. Weinhouse S. Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: GHA Clowes memorial lecture. Cancer Res 1972; 32:2007-2016.
59. Weinhouse S, Langan J, Shatton JA, Morris HP. Fatty acids as metabolic fuels of cancer cells. In: Wood JG, editor. Tumor lipids. Chicago: American Oil Chemists Society Press; 1973. pp. 14-20.
60. Wagle SR, Morris HP, Weber G. Comparative biochemistry of hepatomas V: Studies on amino acid incorporation in liver tumors of different growth rates. Cancer Res 1963; 23:1003-1007.
61. Kovacevic Z, Morris HP. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res 1972; 32:326-333.
62. Rossignol R, Gilkerson R, Aggeler R, et al. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004; 64:985-993.
63. Coleman PS. Membrane cholesterol and tumor bioenergetics. Ann N Y Acad Sci 1986; 488:451-467.
64. Parlo RA, Coleman PS. Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria: the truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. J Biol Chem 1984; 259:9997-10003.
65. 2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. Biochim Biophys Acta 1986; 886:169-176.
66. Yarian CS, Toroser D, Sohal RS. Aconitase is the main functional target of aging in the citric acid cycle of kidney mitochondria from mice. Mech Ageing Dev 2006; 127:79-84. This paper links ageing processes with reduction of aconitase activity, which potentially links ROS to impaired Krebs-cycle acitivity specifically with increasing age.
67. Abreu LA, Abreu RR. Changes induced by Ehrlich ascites carcinoma in hepatic fumarase and aconitase activities. Experientia 1978; 34:1536.
68. Hernanz A, de la Fuente M. Characterization of aconitate hydratase from mitochondria and cytoplasm of ascites tumor cells. Biochem Cell Biol 1988; 66:792-795.
69. Kimura Y, Niwa T, Wada E, Komeiji T. Incorporation of labeled glucose-carbon into different fractions of Ehrlich ascites tumor cells, with special reference to lipogenesis from glucose. Jpn J Exp Med 1964; 34:267-291.
70. Szutowicz A, Kwiatkowski J, Angielski S. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br J Cancer 1979; 39:681-687.
71. Kuhajda FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 1994; 91:6379-6383.
72. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005; 65:6719-6725. The authors show that inhibition of energy storage pathways in cancer cells may inhibit growth - in addition to their intriguing findings employing an AMP-kinase activator, AICA riboside.
73. Wang YL, Frauwirth KA, Rangwala SM, et al. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002; 277:31781-31788.
74. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta 2002; 1576:1-14.
75. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24:78-90.
76. Cam H, Balciunaite E, Blais A, et al. A common set of gene regulatory networks links metabolism and growth inhibition. Mol Cell 2004; 16:399-411.
77. Mühlenhoff U, Richhardt N, Ristow M, et al. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet 2002; 11:2025-2036.
78. McKusick VA, Kniffin CL, Tiller GE, et al. Online mendelian inheritance in man: Friedreich Ataxia (OMIM 229300); 2006. http://www.ncbi.nlm.nih.gov/en- trez/dispomim.cgi?id=229300 [last accessed 15 January 2006].
79. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82:510-529.
80. Ristow M, Pfister MF, Yee AJ, et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci USA 2000; 97:12239-12243.
81. Vorgerd M, Schöls L, Hardt C, et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 2000; 10:430-435.
82. Thierbach R, Schulz TJ, Isken F, et al. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span, and tumor growth in mice. Hum Mol Genet 2005; 14:3857-3864. Demonstration that impaired Fe/S cluster synthesis causes tumors in mice.
83. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848-851.
84. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26:268-270.
85. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69:49-54.
86. Rustin P, Rotig A. Inborn errors of complex II: unusual human mitochondrial diseases. Biochim Biophys Acta 2002; 1553:117-122.
87. Briere JJ, Favier J, Benit P, et al. Mitochondrial succinate is instrumental for HIF1 alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum Mol Genet 2005; 14:3263-3269. Links an organic acid and intermediate metabolite of the Krebs cycle, succinate, with cancer growth via activation of the HIF1α/VHL pathway.
88. Dahia PLM, Ross KN, Wright ME, et al. A HIF1 a regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 2005; 1:e8. Links an organic acid and intermediate metabolite of the Krebs cycle, succinate, with cancer growth via activation of the HIF1α/VHL pathway.
89. Selak MA, Armour SM, Mackenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7:77-85. Links an organic acid and intermediate metabolite of the Krebs cycle, succinate, with cancer growth via activation of the HIF1α/VHL pathway.
90. Simonnet H, Alazard N, Pfeiffer K, et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002; 23:759-768.
91. Simonnet H, Demont J, Pfeiffer K, et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 2003; 24:1461-1466.
92. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406-410.
93. Rustin P. Mitochondria, from cell death to proliferation. Nat Genet 2002; 30:352-353.
94. McCay CM, Crowel MF, Maynard LA. The effect of retarded growth upon the length of the life span and upon ultimate body size. J Nutr 1935; 10:63-79.
95. Weindruch R, Walford RL. The retardation of aging and disease by dietary restriction. Springfield, IL: Charles C. Thomas Pub Ltd; 1988.
96. Zhu Z, Jiang W, McGinley JN, Thompson HJ. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res 2005; 65:7023-7030. Mimicking caloric restriction by interference with glucose metabolism inhibits cancer growth.
97. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996; 273:59-63.
98. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39:359-407.
99. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82:47-95.
100. Lin SJ, Kaeberlein M, Andalis AA, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature 2002; 418:344-348.
101. Ristow M, Mulder H, Pomplun D, et al. Frataxin-deficiency in pancreatic islets causes diabetes due to loss of beta-cell mass. J Clin Invest 2003; 112:527-534.
102. Schulz TJ, Thierbach R, Voigt A, et al. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 2006; 281:977-981. Proof that re-instatement of OXPHOS in cancer cells efficiently blocks cancer growth.
103. van Waveren C, Sun Y, Cheung HS, Moraes CT. Oxidative phosphorylation dysfunction modulates expression of extracellular matrix: remodeling genes and invasion. Carcinogenesis 2006; 27:409-418. Suggestive evidence that tumor cell invasiveness and OXPHOS may be functionally linked.
104. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005; 102:5992-5997. Important paper showing that stepwise derangement of cell cycle control causes equally stepwise alterations of glycolysis and OXPHOS.